Abstract:Cancer remains a major global cause of death, posing significant treatment challenges. The interactions between tumor cells and the tumor microenvironment (TME) are crucial in influencing tumor initiation, progression, metastasis, and treatment response. There has been significant research and clinical interest in targeting the TME as a therapeutic approach in cancer, with advancements being made through drug development. Histamine binds to HRH1 receptors on the TME, which inhibit CD8+ T cell activity, promote tumor growth, and contribute to resistance against immunotherapy. By inhibiting CD8+ T cells, the effectiveness of immunotherapies targeting these cells is reduced. By blocking the HRH1 pathway, H1-antihistamines can mitigate this suppression and enhance the response to immunotherapies that target CD8+ T cells. Therefore, understanding the role of histamine and its potential impact on T cells and the role of H1-antihistamines in improving immune-oncology (I/O) agents' efficacy ultimately could lead to more effective cancer therapies. The objective of this review is to examine the current literature to investigate the potential role of H1-antihistamines on the effectiveness of I/O drugs and their role in enhancing treatment against cancer. We conducted a comprehensive literature search, which included multiple databases including PubMed, Google Scholar, and EMBASE, as well as a search of oncology congresses. Our literature review initially identified thirty studies. Twenty-three of these were excluded for failing to meet inclusion criteria, which varied from study design to the type of antihistamines and patient populations involved. The clinical studies investigated the effect of different generations of H1-antihistamines in combination with I/O treatments on patients' outcomes. The findings from these studies indicated that patients using H1-antihistamines concomitantly with I/O agents experienced longer median overall survival (mOS), progression-free survival (mPFS), or improved survival compared to those who did not use antihistamines. Additionally, these trials differentiated between cationic and non-cationic H1-antihistamines, revealing that users of cationic antihistamines had overall better outcomes in terms of longer mOS and mPFS. The assessed trials were consistent in their comparisons of quantitative and qualitative, efficacy, and safety outcomes. Checkpoint inhibitors represent a significant breakthrough in cancer treatment; however, only 20-40% of patients respond to immunotherapies due to many factors, among them the highly immunosuppressive conditions of the TME in some cancer types. H1-antihistamines have been shown to potentiate the activity of immunotherapy by enhancing T cell activation in the TME. We reviewed the role of H1-antihistamines on clinical activity of immuno-oncology agents and integrated key clinical studies into a comprehensive resource for the first time, offering invaluable insights for future research. Drawing from our extensive experience in immuno-oncology clinical trials, the manuscript also provides practical recommendations for future research and therapeutic strategies to be implemented effectively.

Combination of H1 and H2 Histamine Receptor Antagonists: Current Knowledge and Perspectives of a Classic Treatment Strategy

Update on Histamine and Antihistamines

New Therapeutics for Allergic Airway Diseases

Histamine pharmacology: from Sir Henry Dale to the 21st century

The Role of Histamine and Histamine Receptors in Mast Cell-Mediated Allergy and Inflammation: The Hunt for New Therapeutic Targets

Opportunities and challenges in the therapeutic exploitation of histamine and histamine receptor pharmacology in inflammation-driven disorders

Advances in clinical application of H1 antihistamines in the treatment of skin diseases.

Targeting Histamine and Histamine Receptors for the Precise Regulation of Feeding

The Antagonistic Activity of H 1 Receptor Antagonists As Medicinal Foods

In Silico Binding Characteristics Between Human Histamine H-1 Receptor and Antagonists

Revisiting Preclinical Observations of Several Histamine H3 Receptor Antagonists/Inverse Agonists in Cognitive Impairment, Anxiety, Depression, and Sleep–Wake Cycle Disorder

Advances on Research of Function and Regulatory Mechanism of Histamine H1 Receptor

Histamine receptors, agonists, and antagonists in health and disease

Computational investigation of interactions between human H2 receptor and its agonists.

Effect of histamine H4 receptor and its antagonist on allergic rhinitis in rats

Enhancing immuno-oncology efficacy with H1-antihistamine in cancer therapy: a review of current research and findings

H2 antihistamines: May be useful for combination therapies in cancer?

Targeting histamine in metabolic syndrome: Insights and therapeutic potential

Histamine and histamine receptors: Roles in major depressive disorder

Structural basis of ligand recognition and design of antihistamines targeting histamine H4 receptor

Progress of Histamine H3 Receptor Antagonist